Loading…
Glucagon-Like Peptide-1 (GLP-1) Treatment Ameliorates Cognitive Impairment by Attenuating Arc Expression in Type 2 Diabetic Rats
BACKGROUND Glucagon-like peptide-1 (GLP-1) has been reported to exert some beneficial effects on the central nervous system (CNS). However, the effect of GLP-1 on cognitive impairment associated with type 2 diabetes is not well known. This study investigated the effect of GLP-1 on ameliorating memor...
Saved in:
Published in: | Medical science monitor 2017-09, Vol.23, p.4334-4342 |
---|---|
Main Authors: | , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c2962-6a90a60b75f8925c46768cf1396380f4fd8f38c18b8ffccfe64c7afded34f9333 |
---|---|
cites | |
container_end_page | 4342 |
container_issue | |
container_start_page | 4334 |
container_title | Medical science monitor |
container_volume | 23 |
creator | Cai, Xiang-Sheng Tan, Zhao-Guang Li, Jing-Jing Gao, Wei-Hong Li, Shu-Ji Li, Jin-Long Tang, Yong-Ming Li, Hong-Wei Hui, Hong-Xiang |
description | BACKGROUND Glucagon-like peptide-1 (GLP-1) has been reported to exert some beneficial effects on the central nervous system (CNS). However, the effect of GLP-1 on cognitive impairment associated with type 2 diabetes is not well known. This study investigated the effect of GLP-1 on ameliorating memory deficits in type 2 diabetic rats. MATERIAL AND METHODS Type 2 diabetic rats were induced by a high-sugar, high-fat diet, followed by streptozotocin (STZ) injection and then tested in the Morris Water Maze (MWM) 1 week after the induction of diabetes. The mRNA expression of Arc, APP, BACE1, and PS1 were determined by real-time quantitative PCR, and the Arc protein was analyzed by immunoblotting and immunohistochemistry. RESULTS Type 2 diabetic rats exhibited a significant decline in learning and memory in the MWM tests, but GLP-1 treatment was able to protect this decline and significantly improved learning ability and memory. The mRNA expression assays showed that GLP-1 treatment markedly reduced Arc, APP, BACE1, and PS1 expressions, which were elevated in the diabetic rats. Immunoblotting and immunohistochemistry results also confirmed that Arc protein increased in the hippocampus of diabetic rats, but was reduced after GLP-1 treatment. CONCLUSIONS Our findings suggest that GLP-1 treatment improves learning and memory deficits in type 2 diabetic rats, and this effect is likely through the reduction of Arc expression in the hippocampus. |
doi_str_mv | 10.12659/MSM.903252 |
format | article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5601394</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1937528807</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2962-6a90a60b75f8925c46768cf1396380f4fd8f38c18b8ffccfe64c7afded34f9333</originalsourceid><addsrcrecordid>eNpVkc1v1DAQxS1ERT_gxB35WIRSHDt27AvSainbSltRwXK2HGe8GBIntZ2KvfVPJ-q2VXuakean90bvIfS-JGclFVx9vvp5daYIo5y-QkelqFjBak5eP9sP0XFKfwihUhD-Bh1SKSVXih-hu1U3WbMdQrH2fwFfw5h9C0WJT1fr66L8iDcRTO4hZLzoofNDNBkSXg7b4LO_BXzZj8bHe6DZ4UXOECaTfdjiRbT4_N8YISU_BOwD3uxGwBR_9aaB7C3-YXJ6iw6c6RK8e5gn6Ne3883yolh_X10uF-vCUiVoIYwiRpCm5k4qym0laiGtK5kSTBJXuVY6Jm0pG-mctQ5EZWvjWmhZ5RRj7AR92euOU9NDa-eHo-n0GH1v4k4PxuuXl-B_6-1wq7kgs0s1C5w-CMThZoKUde-Tha4zAYYp6VLNSc_BknpGP-1RG4eUIrgnm5Lo-8703JnedzbTH55_9sQ-lsT-AxnTkxU</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1937528807</pqid></control><display><type>article</type><title>Glucagon-Like Peptide-1 (GLP-1) Treatment Ameliorates Cognitive Impairment by Attenuating Arc Expression in Type 2 Diabetic Rats</title><source>PMC (PubMed Central)</source><creator>Cai, Xiang-Sheng ; Tan, Zhao-Guang ; Li, Jing-Jing ; Gao, Wei-Hong ; Li, Shu-Ji ; Li, Jin-Long ; Tang, Yong-Ming ; Li, Hong-Wei ; Hui, Hong-Xiang</creator><creatorcontrib>Cai, Xiang-Sheng ; Tan, Zhao-Guang ; Li, Jing-Jing ; Gao, Wei-Hong ; Li, Shu-Ji ; Li, Jin-Long ; Tang, Yong-Ming ; Li, Hong-Wei ; Hui, Hong-Xiang</creatorcontrib><description>BACKGROUND Glucagon-like peptide-1 (GLP-1) has been reported to exert some beneficial effects on the central nervous system (CNS). However, the effect of GLP-1 on cognitive impairment associated with type 2 diabetes is not well known. This study investigated the effect of GLP-1 on ameliorating memory deficits in type 2 diabetic rats. MATERIAL AND METHODS Type 2 diabetic rats were induced by a high-sugar, high-fat diet, followed by streptozotocin (STZ) injection and then tested in the Morris Water Maze (MWM) 1 week after the induction of diabetes. The mRNA expression of Arc, APP, BACE1, and PS1 were determined by real-time quantitative PCR, and the Arc protein was analyzed by immunoblotting and immunohistochemistry. RESULTS Type 2 diabetic rats exhibited a significant decline in learning and memory in the MWM tests, but GLP-1 treatment was able to protect this decline and significantly improved learning ability and memory. The mRNA expression assays showed that GLP-1 treatment markedly reduced Arc, APP, BACE1, and PS1 expressions, which were elevated in the diabetic rats. Immunoblotting and immunohistochemistry results also confirmed that Arc protein increased in the hippocampus of diabetic rats, but was reduced after GLP-1 treatment. CONCLUSIONS Our findings suggest that GLP-1 treatment improves learning and memory deficits in type 2 diabetic rats, and this effect is likely through the reduction of Arc expression in the hippocampus.</description><identifier>ISSN: 1643-3750</identifier><identifier>ISSN: 1234-1010</identifier><identifier>EISSN: 1643-3750</identifier><identifier>DOI: 10.12659/MSM.903252</identifier><identifier>PMID: 28885995</identifier><language>eng</language><publisher>United States: International Scientific Literature, Inc</publisher><subject>Animal Study ; Animals ; Blood Glucose - metabolism ; Cognitive Dysfunction - blood ; Cognitive Dysfunction - drug therapy ; Cognitive Dysfunction - metabolism ; Cytoskeletal Proteins - metabolism ; Diabetes Mellitus, Experimental - metabolism ; Diabetes Mellitus, Type 2 - blood ; Diabetes Mellitus, Type 2 - drug therapy ; Diabetes Mellitus, Type 2 - metabolism ; Diet, High-Fat - adverse effects ; Disease Models, Animal ; Glucagon-Like Peptide 1 - pharmacology ; Hippocampus - drug effects ; Male ; Maze Learning - drug effects ; Memory Disorders - complications ; Nerve Tissue Proteins - metabolism ; Rats ; Rats, Sprague-Dawley</subject><ispartof>Medical science monitor, 2017-09, Vol.23, p.4334-4342</ispartof><rights>Med Sci Monit, 2017 2017</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c2962-6a90a60b75f8925c46768cf1396380f4fd8f38c18b8ffccfe64c7afded34f9333</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5601394/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5601394/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27903,27904,53769,53771</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28885995$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cai, Xiang-Sheng</creatorcontrib><creatorcontrib>Tan, Zhao-Guang</creatorcontrib><creatorcontrib>Li, Jing-Jing</creatorcontrib><creatorcontrib>Gao, Wei-Hong</creatorcontrib><creatorcontrib>Li, Shu-Ji</creatorcontrib><creatorcontrib>Li, Jin-Long</creatorcontrib><creatorcontrib>Tang, Yong-Ming</creatorcontrib><creatorcontrib>Li, Hong-Wei</creatorcontrib><creatorcontrib>Hui, Hong-Xiang</creatorcontrib><title>Glucagon-Like Peptide-1 (GLP-1) Treatment Ameliorates Cognitive Impairment by Attenuating Arc Expression in Type 2 Diabetic Rats</title><title>Medical science monitor</title><addtitle>Med Sci Monit</addtitle><description>BACKGROUND Glucagon-like peptide-1 (GLP-1) has been reported to exert some beneficial effects on the central nervous system (CNS). However, the effect of GLP-1 on cognitive impairment associated with type 2 diabetes is not well known. This study investigated the effect of GLP-1 on ameliorating memory deficits in type 2 diabetic rats. MATERIAL AND METHODS Type 2 diabetic rats were induced by a high-sugar, high-fat diet, followed by streptozotocin (STZ) injection and then tested in the Morris Water Maze (MWM) 1 week after the induction of diabetes. The mRNA expression of Arc, APP, BACE1, and PS1 were determined by real-time quantitative PCR, and the Arc protein was analyzed by immunoblotting and immunohistochemistry. RESULTS Type 2 diabetic rats exhibited a significant decline in learning and memory in the MWM tests, but GLP-1 treatment was able to protect this decline and significantly improved learning ability and memory. The mRNA expression assays showed that GLP-1 treatment markedly reduced Arc, APP, BACE1, and PS1 expressions, which were elevated in the diabetic rats. Immunoblotting and immunohistochemistry results also confirmed that Arc protein increased in the hippocampus of diabetic rats, but was reduced after GLP-1 treatment. CONCLUSIONS Our findings suggest that GLP-1 treatment improves learning and memory deficits in type 2 diabetic rats, and this effect is likely through the reduction of Arc expression in the hippocampus.</description><subject>Animal Study</subject><subject>Animals</subject><subject>Blood Glucose - metabolism</subject><subject>Cognitive Dysfunction - blood</subject><subject>Cognitive Dysfunction - drug therapy</subject><subject>Cognitive Dysfunction - metabolism</subject><subject>Cytoskeletal Proteins - metabolism</subject><subject>Diabetes Mellitus, Experimental - metabolism</subject><subject>Diabetes Mellitus, Type 2 - blood</subject><subject>Diabetes Mellitus, Type 2 - drug therapy</subject><subject>Diabetes Mellitus, Type 2 - metabolism</subject><subject>Diet, High-Fat - adverse effects</subject><subject>Disease Models, Animal</subject><subject>Glucagon-Like Peptide 1 - pharmacology</subject><subject>Hippocampus - drug effects</subject><subject>Male</subject><subject>Maze Learning - drug effects</subject><subject>Memory Disorders - complications</subject><subject>Nerve Tissue Proteins - metabolism</subject><subject>Rats</subject><subject>Rats, Sprague-Dawley</subject><issn>1643-3750</issn><issn>1234-1010</issn><issn>1643-3750</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNpVkc1v1DAQxS1ERT_gxB35WIRSHDt27AvSainbSltRwXK2HGe8GBIntZ2KvfVPJ-q2VXuakean90bvIfS-JGclFVx9vvp5daYIo5y-QkelqFjBak5eP9sP0XFKfwihUhD-Bh1SKSVXih-hu1U3WbMdQrH2fwFfw5h9C0WJT1fr66L8iDcRTO4hZLzoofNDNBkSXg7b4LO_BXzZj8bHe6DZ4UXOECaTfdjiRbT4_N8YISU_BOwD3uxGwBR_9aaB7C3-YXJ6iw6c6RK8e5gn6Ne3883yolh_X10uF-vCUiVoIYwiRpCm5k4qym0laiGtK5kSTBJXuVY6Jm0pG-mctQ5EZWvjWmhZ5RRj7AR92euOU9NDa-eHo-n0GH1v4k4PxuuXl-B_6-1wq7kgs0s1C5w-CMThZoKUde-Tha4zAYYp6VLNSc_BknpGP-1RG4eUIrgnm5Lo-8703JnedzbTH55_9sQ-lsT-AxnTkxU</recordid><startdate>20170908</startdate><enddate>20170908</enddate><creator>Cai, Xiang-Sheng</creator><creator>Tan, Zhao-Guang</creator><creator>Li, Jing-Jing</creator><creator>Gao, Wei-Hong</creator><creator>Li, Shu-Ji</creator><creator>Li, Jin-Long</creator><creator>Tang, Yong-Ming</creator><creator>Li, Hong-Wei</creator><creator>Hui, Hong-Xiang</creator><general>International Scientific Literature, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20170908</creationdate><title>Glucagon-Like Peptide-1 (GLP-1) Treatment Ameliorates Cognitive Impairment by Attenuating Arc Expression in Type 2 Diabetic Rats</title><author>Cai, Xiang-Sheng ; Tan, Zhao-Guang ; Li, Jing-Jing ; Gao, Wei-Hong ; Li, Shu-Ji ; Li, Jin-Long ; Tang, Yong-Ming ; Li, Hong-Wei ; Hui, Hong-Xiang</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2962-6a90a60b75f8925c46768cf1396380f4fd8f38c18b8ffccfe64c7afded34f9333</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Animal Study</topic><topic>Animals</topic><topic>Blood Glucose - metabolism</topic><topic>Cognitive Dysfunction - blood</topic><topic>Cognitive Dysfunction - drug therapy</topic><topic>Cognitive Dysfunction - metabolism</topic><topic>Cytoskeletal Proteins - metabolism</topic><topic>Diabetes Mellitus, Experimental - metabolism</topic><topic>Diabetes Mellitus, Type 2 - blood</topic><topic>Diabetes Mellitus, Type 2 - drug therapy</topic><topic>Diabetes Mellitus, Type 2 - metabolism</topic><topic>Diet, High-Fat - adverse effects</topic><topic>Disease Models, Animal</topic><topic>Glucagon-Like Peptide 1 - pharmacology</topic><topic>Hippocampus - drug effects</topic><topic>Male</topic><topic>Maze Learning - drug effects</topic><topic>Memory Disorders - complications</topic><topic>Nerve Tissue Proteins - metabolism</topic><topic>Rats</topic><topic>Rats, Sprague-Dawley</topic><toplevel>online_resources</toplevel><creatorcontrib>Cai, Xiang-Sheng</creatorcontrib><creatorcontrib>Tan, Zhao-Guang</creatorcontrib><creatorcontrib>Li, Jing-Jing</creatorcontrib><creatorcontrib>Gao, Wei-Hong</creatorcontrib><creatorcontrib>Li, Shu-Ji</creatorcontrib><creatorcontrib>Li, Jin-Long</creatorcontrib><creatorcontrib>Tang, Yong-Ming</creatorcontrib><creatorcontrib>Li, Hong-Wei</creatorcontrib><creatorcontrib>Hui, Hong-Xiang</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Medical science monitor</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cai, Xiang-Sheng</au><au>Tan, Zhao-Guang</au><au>Li, Jing-Jing</au><au>Gao, Wei-Hong</au><au>Li, Shu-Ji</au><au>Li, Jin-Long</au><au>Tang, Yong-Ming</au><au>Li, Hong-Wei</au><au>Hui, Hong-Xiang</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Glucagon-Like Peptide-1 (GLP-1) Treatment Ameliorates Cognitive Impairment by Attenuating Arc Expression in Type 2 Diabetic Rats</atitle><jtitle>Medical science monitor</jtitle><addtitle>Med Sci Monit</addtitle><date>2017-09-08</date><risdate>2017</risdate><volume>23</volume><spage>4334</spage><epage>4342</epage><pages>4334-4342</pages><issn>1643-3750</issn><issn>1234-1010</issn><eissn>1643-3750</eissn><abstract>BACKGROUND Glucagon-like peptide-1 (GLP-1) has been reported to exert some beneficial effects on the central nervous system (CNS). However, the effect of GLP-1 on cognitive impairment associated with type 2 diabetes is not well known. This study investigated the effect of GLP-1 on ameliorating memory deficits in type 2 diabetic rats. MATERIAL AND METHODS Type 2 diabetic rats were induced by a high-sugar, high-fat diet, followed by streptozotocin (STZ) injection and then tested in the Morris Water Maze (MWM) 1 week after the induction of diabetes. The mRNA expression of Arc, APP, BACE1, and PS1 were determined by real-time quantitative PCR, and the Arc protein was analyzed by immunoblotting and immunohistochemistry. RESULTS Type 2 diabetic rats exhibited a significant decline in learning and memory in the MWM tests, but GLP-1 treatment was able to protect this decline and significantly improved learning ability and memory. The mRNA expression assays showed that GLP-1 treatment markedly reduced Arc, APP, BACE1, and PS1 expressions, which were elevated in the diabetic rats. Immunoblotting and immunohistochemistry results also confirmed that Arc protein increased in the hippocampus of diabetic rats, but was reduced after GLP-1 treatment. CONCLUSIONS Our findings suggest that GLP-1 treatment improves learning and memory deficits in type 2 diabetic rats, and this effect is likely through the reduction of Arc expression in the hippocampus.</abstract><cop>United States</cop><pub>International Scientific Literature, Inc</pub><pmid>28885995</pmid><doi>10.12659/MSM.903252</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1643-3750 |
ispartof | Medical science monitor, 2017-09, Vol.23, p.4334-4342 |
issn | 1643-3750 1234-1010 1643-3750 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5601394 |
source | PMC (PubMed Central) |
subjects | Animal Study Animals Blood Glucose - metabolism Cognitive Dysfunction - blood Cognitive Dysfunction - drug therapy Cognitive Dysfunction - metabolism Cytoskeletal Proteins - metabolism Diabetes Mellitus, Experimental - metabolism Diabetes Mellitus, Type 2 - blood Diabetes Mellitus, Type 2 - drug therapy Diabetes Mellitus, Type 2 - metabolism Diet, High-Fat - adverse effects Disease Models, Animal Glucagon-Like Peptide 1 - pharmacology Hippocampus - drug effects Male Maze Learning - drug effects Memory Disorders - complications Nerve Tissue Proteins - metabolism Rats Rats, Sprague-Dawley |
title | Glucagon-Like Peptide-1 (GLP-1) Treatment Ameliorates Cognitive Impairment by Attenuating Arc Expression in Type 2 Diabetic Rats |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-25T22%3A12%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Glucagon-Like%20Peptide-1%20(GLP-1)%20Treatment%20Ameliorates%20Cognitive%20Impairment%20by%20Attenuating%20Arc%20Expression%20in%20Type%202%20Diabetic%20Rats&rft.jtitle=Medical%20science%20monitor&rft.au=Cai,%20Xiang-Sheng&rft.date=2017-09-08&rft.volume=23&rft.spage=4334&rft.epage=4342&rft.pages=4334-4342&rft.issn=1643-3750&rft.eissn=1643-3750&rft_id=info:doi/10.12659/MSM.903252&rft_dat=%3Cproquest_pubme%3E1937528807%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c2962-6a90a60b75f8925c46768cf1396380f4fd8f38c18b8ffccfe64c7afded34f9333%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1937528807&rft_id=info:pmid/28885995&rfr_iscdi=true |